A Biochemical/Biophysical Assay Dyad for HTS-Compatible Triaging of Inhibitors of the HIV-1 Nef/Hck SH3 Interaction

Sebastian Breuer; Sheryll Espinola; Xavier Morelli; Bruce E Torbett; Stefan T. Arold; Ingo H Engels

doi:10.2174/2213988501307010016

A Biochemical/Biophysical Assay Dyad for HTS-Compatible Triaging of Inhibitors of the HIV-1 Nef/Hck SH3 Interaction

Sebastian Breuer, Sheryll Espinola, Xavier Morelli, Bruce E Torbett, Stefan T. Arold, Ingo H Engels

Research output: Contribution to journal › Article › peer-review

Abstract

The current treatment regimens for HIV include over 20 anti-retrovirals. However, adverse drug effects and the emergence of drug resistance necessitates the continued improvement of the existing drug classes as well as the development of novel drugs that target as yet therapeutically unexploited viral and cellular pathways. Here we demonstrate a strategy for the discovery of protein-protein interaction inhibitors of the viral pathogenicity factor HIV-1 Nef and its interaction with the host factor SH3. A combination of a time-resolved fluorescence resonance energy resonance energy transfer-based assay and a label-free resonant waveguide grating-based assay was optimized for high-throughput screening formats.

Original language	English (US)
Pages (from-to)	16-20
Number of pages	5
Journal	Current Chemical Genomics and Translational Medicine
Volume	7
DOIs	https://doi.org/10.2174/2213988501307010016
State	Published - Jul 26 2013

Bibliographical note

KAUST Repository Item: Exported on 2020-10-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/2213988501307010016

https://repository.kaust.edu.sa/bitstream/10754/334597/1/Article-Current_Ch-A_Biochemi-2013-07-26.pdf

Cite this

@article{bc7f09fae7ef4e4eaed356234e7324a5,

title = "A Biochemical/Biophysical Assay Dyad for HTS-Compatible Triaging of Inhibitors of the HIV-1 Nef/Hck SH3 Interaction",

abstract = "The current treatment regimens for HIV include over 20 anti-retrovirals. However, adverse drug effects and the emergence of drug resistance necessitates the continued improvement of the existing drug classes as well as the development of novel drugs that target as yet therapeutically unexploited viral and cellular pathways. Here we demonstrate a strategy for the discovery of protein-protein interaction inhibitors of the viral pathogenicity factor HIV-1 Nef and its interaction with the host factor SH3. A combination of a time-resolved fluorescence resonance energy resonance energy transfer-based assay and a label-free resonant waveguide grating-based assay was optimized for high-throughput screening formats.",

author = "Sebastian Breuer and Sheryll Espinola and Xavier Morelli and Torbett, {Bruce E} and Arold, {Stefan T.} and Engels, {Ingo H}",

note = "KAUST Repository Item: Exported on 2020-10-01",

year = "2013",

month = jul,

day = "26",

doi = "10.2174/2213988501307010016",

language = "English (US)",

volume = "7",

pages = "16--20",

journal = "Current Chemical Genomics and Translational Medicine",

issn = "2213-9885",

publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - A Biochemical/Biophysical Assay Dyad for HTS-Compatible Triaging of Inhibitors of the HIV-1 Nef/Hck SH3 Interaction

AU - Breuer, Sebastian

AU - Espinola, Sheryll

AU - Morelli, Xavier

AU - Torbett, Bruce E

AU - Arold, Stefan T.

AU - Engels, Ingo H

N1 - KAUST Repository Item: Exported on 2020-10-01

PY - 2013/7/26

Y1 - 2013/7/26

N2 - The current treatment regimens for HIV include over 20 anti-retrovirals. However, adverse drug effects and the emergence of drug resistance necessitates the continued improvement of the existing drug classes as well as the development of novel drugs that target as yet therapeutically unexploited viral and cellular pathways. Here we demonstrate a strategy for the discovery of protein-protein interaction inhibitors of the viral pathogenicity factor HIV-1 Nef and its interaction with the host factor SH3. A combination of a time-resolved fluorescence resonance energy resonance energy transfer-based assay and a label-free resonant waveguide grating-based assay was optimized for high-throughput screening formats.

AB - The current treatment regimens for HIV include over 20 anti-retrovirals. However, adverse drug effects and the emergence of drug resistance necessitates the continued improvement of the existing drug classes as well as the development of novel drugs that target as yet therapeutically unexploited viral and cellular pathways. Here we demonstrate a strategy for the discovery of protein-protein interaction inhibitors of the viral pathogenicity factor HIV-1 Nef and its interaction with the host factor SH3. A combination of a time-resolved fluorescence resonance energy resonance energy transfer-based assay and a label-free resonant waveguide grating-based assay was optimized for high-throughput screening formats.

UR - http://hdl.handle.net/10754/334597

UR - http://benthamopen.com/ABSTRACT/CCGTM-7-16

U2 - 10.2174/2213988501307010016

DO - 10.2174/2213988501307010016

M3 - Article

C2 - 24396731

SN - 2213-9885

VL - 7

SP - 16

EP - 20

JO - Current Chemical Genomics and Translational Medicine

JF - Current Chemical Genomics and Translational Medicine

ER -

A Biochemical/Biophysical Assay Dyad for HTS-Compatible Triaging of Inhibitors of the HIV-1 Nef/Hck SH3 Interaction

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this